Christopher Cabell - 05 Jan 2026 Form 4 Insider Report for Inhibikase Therapeutics, Inc. (IKT)

Reporting relationship: President & Head of R&D
Issuer ticker: IKT
Reported as of: 05 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Jan 2026, 16:21:52 UTC
Prior SEC filing: 02 Jul 2025
Next SEC filing: 24 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Mark Iwicki, attorney-in-fact

Key filing fact

Christopher Cabell filed Form 4 for Inhibikase Therapeutics, Inc. (IKT) on 07 Jan 2026.

Key facts

This page summarizes Christopher Cabell's Form 4 filing for Inhibikase Therapeutics, Inc. (IKT).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 07 Jan 2026, 16:21.

Change

Previous filing in this sequence was filed on 02 Jul 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001814928 Primary reporting owner

Cabell Christopher

Relationship: President & Head of R&D
Address: 1000 N. WEST STREET, SUITE 1200, WILMINGTON
Signature: /s/ Mark Iwicki, attorney-in-fact
Signature date: 07 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IKT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +900,117
Change %
Price: $0.000000
Shares after: 900,117
Date: 05 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 900,117
Exercise price: $2.01
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares underlying the option shall vest and become exercisable in 36 equal monthly installments commencing from January 5, 2026, subject to the Reporting Person's continued employment through each such vesting date.